Short answer
Health Catalyst, Inc. (HCAT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Full repayment of Credit Facility on July 31, 2026 using Disposition proceeds and cash on hand.
Health Catalyst, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Full repayment of Credit Facility on July 31, 2026 using Disposition proceeds and cash on hand
- $122.8M initial term loan and $37.1M delayed draw facility principal repaid
- $3.2M prepayment premium, $548,022 accrued interest, and other fees paid
- Debt facility terminated ahead of July 16, 2029 maturity, with all related liens released
Item 2.01 · Completion of Acquisition or Disposition of Assets
- VitalWare divested to Med-Metrix for $147 million base consideration, subject to customary closing adjustments
- Net proceeds plus cash on hand used to fully prepay and terminate Health Catalyst’s Credit Facility
- Transaction shifts VitalWare operations out of Health Catalyst and reduces outstanding debt obligations
- Transition services to Buyer continue for specified periods of up to six months
Item 2.02 · Results of Operations and Financial Condition
- Health Catalyst reported financial results for the quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Disclosure furnished under Item 2.02, limiting Section 18 liability and incorporation by reference
Item 7.01 · Regulation FD Disclosure
- Health Catalyst completed a disposition with the Buyer, marking a finalized asset or business sale
- Transaction completion may reshape portfolio focus and future revenue mix
- Exhibit 99.2 contains the press release with transaction details relevant to valuation and financial impact
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $70.5M, down 13% YoY, reflecting continued contraction despite exceeding company guidance
- Adjusted EBITDA $9.9M, up 6% YoY, while GAAP net loss remained severe at $40.5M
- Adjusted gross margin improved to 51% from 50%, led by professional services margin rising to 22% from 18%
- Cash and equivalents $60.6M plus short-term investments $42.9M, with $151.9M long-term debt still reported
- Q3 guidance: revenue $55M-$56M and Adjusted EBITDA $0-$0.5M; full-year revenue $246M-$249M and EBITDA $18M-$18.5M
Item EX-99.2 · Exhibit EX-99.2
- Vitalware sale closed July 31, 2026, delivering $147 million in total cash consideration, subject to customary adjustments
- Proceeds plus cash on hand fully repaid and terminated the credit facility, eliminating approximately $19 million in annual GAAP interest expense
- Divestiture sharpens focus on healthcare intelligence products combining client data, AI, proprietary benchmarks, and improvement expertise
- Strategic platform includes $2.8 billion in documented outcomes across more than 380 client improvement case studies
- Debt retirement strengthens financial flexibility, but execution risk remains around converting the focused product strategy into growth
Item EX-99.3 · Exhibit EX-99.3
- VitalWare divestiture generated $147.0M gross proceeds and $145.2M net cash after approximately $1.8M transaction costs
- Pro forma gain on sale: $65.9M, with no related tax provision due to substantial deferred tax asset valuation allowances
- Entire $159.9M term loan principal repaid, requiring $166.4M cash including accrued interest and early termination fees
- Debt extinguishment creates a $9.7M loss, but removes estimated interest expense of $9.4M for six months and $22.1M annually
- Post-divestiture pro forma revenue falls to $274.3M for 2025, while net loss improves to $112.2M from $178.0M primarily through debt savings and the sale gain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Health Catalyst, Inc. 8-K filings
Get the next HCAT 8-K as it lands
Follow HCAT for push alerts, or ask the research agent what this filing means.